Research ArticleClinical Investigation
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler and Johannes Czernin
Journal of Nuclear Medicine October 2021, 62 (10) 1440-1446; DOI: https://doi.org/10.2967/jnumed.121.261982
Jeremie Calais
Andrei Gafita
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Matthias Eiber
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
5Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
Wesley R. Armstrong
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Jeannine Gartmann
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Pan Thin
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Kathleen Nguyen
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Vincent Lok
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Laura Gosa
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Tristan Grogan
6Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;
Rouzbeh Esfandiari
7Excel Diagnostics and Nuclear Oncology Center, Houston, Texas;
Martin Allen-Auerbach
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
3Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
4Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;
Andrew Quon
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
3Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
4Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;
Shadfar Bahri
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
3Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
4Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;
Pawan Gupta
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Linda Gardner
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
David Ranganathan
8RadioMedix, Inc., Houston, Texas; and
Roger Slavik
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
Magnus Dahlbom
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
2Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;
Ken Herrmann
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
9Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
Ebrahim Delpassand
7Excel Diagnostics and Nuclear Oncology Center, Houston, Texas;
8RadioMedix, Inc., Houston, Texas; and
Wolfgang P. Fendler
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
9Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
Johannes Czernin
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
3Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
4Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 10
October 1, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler, Johannes Czernin
Journal of Nuclear Medicine Oct 2021, 62 (10) 1440-1446; DOI: 10.2967/jnumed.121.261982
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
Jeremie Calais, Andrei Gafita, Matthias Eiber, Wesley R. Armstrong, Jeannine Gartmann, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Tristan Grogan, Rouzbeh Esfandiari, Martin Allen-Auerbach, Andrew Quon, Shadfar Bahri, Pawan Gupta, Linda Gardner, David Ranganathan, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Ebrahim Delpassand, Wolfgang P. Fendler, Johannes Czernin
Journal of Nuclear Medicine Oct 2021, 62 (10) 1440-1446; DOI: 10.2967/jnumed.121.261982
Jump to section
Related Articles
Cited By...
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
- Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
- SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer--Use of Imaging Agents in Therapeutic Drug Development and Approval
- From Concept to Regulatory Drug Approval: Lessons for Theranostics
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice